Discordant Resistance to Kanamycin and Amikacin in Drug-Resistant Mycobacterium tuberculosis-Reference-Cited by-同舟云学术

Discordant Resistance to Kanamycin and Amikacin in Drug-Resistant Mycobacterium tuberculosis

Published:2003-09 Issue:9 Volume:47 Page:2971-2973
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Krüüner Annika¹²³,Jureen Pontus¹,Levina Klavdia⁴,Ghebremichael Solomon¹,Hoffner Sven¹

Affiliation:

1. Department of Bacteriology, Swedish Institute for Infectious Disease Control

2. Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden

3. Department of Mycobacteriology, United Laboratory, Tartu University Clinics, Tartu

4. North-Estonian Regional Hospital, Tallinn, Estonia

Abstract

ABSTRACT It is generally thought that there is full cross-resistance in Mycobacterium tuberculosis between the aminoglycoside drugs kanamycin and amikacin. However, kanamycin resistance and amikacin susceptibility were seen in 43 of 79 (54%) multidrug-resistant Estonian isolates, indicating that there might be a need to test the resistance of M. tuberculosis isolates to both drugs.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.47.9.2971-2973.2003

Reference26 articles.

1. Mechanism of Resistance to Amikacin and Kanamycin in Mycobacterium tuberculosis

2. Ayvazian L. F. 1993. Tuberculosis—a comprehensive international approach p. 1-20. In L. B. Reichman and E. S. Hershfield (ed.) History of tuberculosis. Marcel Dekker Inc. New York N.Y.

3. Böttger, E. C. 1994. Resistance to drugs targeting protein synthesis in mycobacteria. Trends Microbiol.2:416-421.

4. Dobner, P., G. Bretzel, S. Rüsch-Gerdes, K. Feldmann, M. Rifai, T. Löscher, and H. Rinder. 1997. Geographic variation of the predictive values of genomic mutations associated with streptomycin resistance in Mycobacterium tuberculosis. Mol. Cell. Probes11:123-126.

5. Espinal, M. A., A. Laszlo, L. Simonsen, F. Boulahbal, S. J. Kim, A. Reniero, S. Hoffner, H. L. Rieder, N. Binkin, C. Dye, R. Williams, and M. C. Raviglione. 2001. Global trends in resistance to antituberculosis drugs. N. Engl. J. Med.344:1294-1303.

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heterologous production of the D-cycloserine intermediate O-acetyl-L-serine in a human type II pulmonary cell model;Scientific Reports;2023-05-26

2. Marine Macrolides to Tackle Antimicrobial Resistance of Mycobacterium tuberculosis;Marine Drugs;2022-11-01

3. Heterologous Production of the D-Cycloserine Intermediate O-acetyl-L-serine in Human Lung Cancer Cells;2022-10-24

4. Mycobacterium simiae Isolates Subtypes and Molecular Drug Susceptibility in Iran;Archives of Clinical Infectious Diseases;2022-09-18

5. Advances in Treatment of Drug-Resistant Pulmonary TB: What Is the Latest Approach to Treat Drug-Resistant Pulmonary TB?;Respiratory Disease Series: Diagnostic Tools and Disease Managements;2022